NCB research note coincides with Tysabri lawsuit

A research note by NCB Stockbrokers may have inadvertently influenced the timing of a US lawsuit taken last week against Elan and Biogen, for an alleged death linked to the clinical trial of withdrawn multiple sclerosis drug Tysabri.

23rd July, 2005

A research note by NCB Stockbrokers may have inadvertently influenced the timing of a US lawsuit taken last week against Elan and Biogen, for an alleged death linked to the clinical trial of withdrawn multiple sclerosis drug Tysabri.

The lawsuit was instigated on behalf of the family of a deceased US patient by New York law specialist Parker & Waichman.

It alleges that the prescription by Elan and its partner Biogen of a combination of...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago